Table 2.
Outcomes by presence of microbleeds
| Variable | Overall, n=404 | With MBs, n=83 | Without MBs, n=321 | P Valuea |
|---|---|---|---|---|
| Composite outcome | 124 (30.7%) | 56 (67.5%) | 68 (21.1%) | <0.001 |
| Kidney outcome | ||||
| Doubling of S-Cre and/or ESRD | 113 (28.0%) | 51 (61.4%) | 62 (19.3%) | <0.001 |
| CVD outcome | ||||
| (1) Death of CVD | 12 (3.0%) | 4 (4.8%) | 8 (2.5%) | 0.28 |
| (2) Ischemic heart disease and/or PAD | 22 (5.4%) | 11 (13.3%) | 11 (3.4%) | <0.001 |
| (3) Stroke | 22 (5.4%) | 13 (15.7%) | 9 (2.8%) | <0.001 |
| 1 + 2 + 3 | 40 (9.9%) | 22 (26.5%) | 18 (5.6%) | <0.001 |
| Lost to follow-upb | 12 (3.0%) | 2 (2.4%) | 10 (3.1%) | 0.28 |
The CVD outcomes included cardiovascular death, new onset of myocardial infarction, coronary revascularization, stroke, and amputation/revascularization because of PAD. Stroke event is brain infarction or brain hemorrhage. MB, microbleed; S-Cre, serum creatinine; CVD, cerebrovascular and cardiovascular disease; PAD, peripheral arterial disease.
a
Log rank tests were used to explore the difference in time to each outcome.
b
Lost patients due to moving or changing hospital.